Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (1116)	8/29/1999 11:27:00 AM
From: William Strop	Read Replies (1) \| Respond to of 1972

Scott, Thanks for the article. To me, it is more positive exposure to the problem of inadequate vaccines for major diseases and the necessity for timely solutions. The accumulated summation of the pressing need & the positive steps that companies like Merck, Vical, etc... are making, will eventually bring about solution(s) and will be followed by an increase of market valuation to the companies in this field, at least IMO. According to Vical IR, the rest of 1999 could bring: 1) the start of Merck's Phase I re: AIDS vaccine; 2) Reports on the Phase II and/or Phase III Allovectin-7 results; and 3) Possible start of Malaria 'Challenge' trials... The continuation of positive development along these fronts coupled with the extraordinary need, will be interesting to watch, IMO... Bill